Volume 19 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(1): 108-112
SUN Yu-jing, LI Yan-hua, LI Jun-wei. The use of antihypertensive drugs with different sustained and controlled release dosage forms in nasal feeding[J]. Chinese Journal of General Practice, 2021, 19(1): 108-112. doi: 10.16766/j.cnki.issn.1674-4152.001743
Citation: SUN Yu-jing, LI Yan-hua, LI Jun-wei. The use of antihypertensive drugs with different sustained and controlled release dosage forms in nasal feeding[J]. Chinese Journal of General Practice, 2021, 19(1): 108-112. doi: 10.16766/j.cnki.issn.1674-4152.001743
shu

The use of antihypertensive drugs with different sustained and controlled release dosage forms in nasal feeding

doi: 10.16766/j.cnki.issn.1674-4152.001743
  • 1.

    The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China

Funds:

 2016ZA102

  • Received Date: 2019-12-15
    Available Online: 2022-02-19
    Abstract
  • The oral solid preparation of antihypertensive drugs has many unreasonable uses in patients with nasal feeding. Most solid preparations cannot be broken and ground after nasal feeding due to their special pharmaceutical technology. In this paper, referring to relevant literature, we summarized the types and structural characteristics of several types of antihypertensive drugs slow and controlled release preparation. To explore the characteristics of different controlled release types of drugs in the use of nasal feeding, and to provide a reference for general practitioners to use the drugs rationally in clinical work. The main types of sustained-release formulations are skeletal sustained-release formulations, membrane controlled-release formulations, osmotic pump sustained-release formulations, enteric-release controlled-release formulations and pellet controlled-release formulations. The commonly used nifedipine controlled release preparations mainly include Bayer company's imported original research drug osmotic pump nifedipine controlled release agent (Adalet), domestic nifedipine sustained release agent for hydrophilic gel matrix type sustained release agent, controlled release tablets for osmotic pump type-controlled release agent. Commonly used metoprolol for imported drugs which Swiss astrazeneca company tartrate metoprolol and succinic acid metoprolol (Betaloc) are ordinary tablets and skeleton type micro pill respectively controlled release agent. And the domestic tartrate metoprolol is mainly based on osmotic pressure release principle with hydroxypropyl methyl cellulose (HPMC)/ethyl cellulose ethoce (EC) as the skeleton of sustained release preparation or capsule preparation. Delayed and controlled release preparation is prohibited to be used for grinding nasal feeding, especially osmotic pump controlled release tablets, because the delayed and controlled release structure is damaged to varying degrees after grinding, the drug enters the blood quickly, and the single dose is several times that of ordinary tablets, which brings great side effects. The frame type sustained-release tablets with scratches can be snapped off and do not grind.

     

    • FullText(HTML)
  • loading
    • References(40)
  • [1]
    WHELTON P K, CAREY R M, ARONOW W S, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the american college of cardiology/american heart association task force on clinical practice guidelines[J]. Hypertension, 2018, 71(6): e140-e144.
    [2]
    ALTREUTER D H, KIRTANE A R, GRANT T, et al. Changing the pill: Developments toward the promise of an ultra-long-acting gastroretentive dosage form[J]. Expert Opin Drug Deliv, 2018, 15(12): 1189-1198. doi: 10.1080/17425247.2018.1544615
    [3]
    AXEL ZEITLER J, RADES T. Interdependence of dosage form microstructure and performance[J]. Pharm Res, 2017, 34(5): 887-889. doi: 10.1007/s11095-017-2137-z
    [4]
    LAU E T L, STEADMAN K J, CICHERO J A Y, et al. Dosage form modification and oral drug delivery in older people[J]. Adv Drug Deliv Rev, 2018, 135: 75-84. doi: 10.1016/j.addr.2018.04.012
    [5]
    杨堆进. 老年患者合理用药的研究进展[J]. 临床合理用药杂志, 2018, 11(9): 174-177. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY201809088.htm
    [6]
    郑东鹏, 卢爱敏, 许友贤. 基于高血压病诊疗实践的上海市慢性病长处方签约服务的效果评价[J]. 中华全科医学, 2019, 17(4): 583-585, 681. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201904019.htm
    [7]
    LI Y, ZHONG M, XIE F, et al. The effect of ph on the stabilization and digestive characteristics of soybean lipophilic protein oil-in-water emulsions with hypromellose[J]. Food Chem, 2020, 309: 125579. doi: 10.1016/j.foodchem.2019.125579
    [8]
    王立, 刘华石, 张文君, 等. 包衣技术在口服固体缓控释制剂中的应用[J]. 药学研究, 2017, 36(2): 108-110. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYG201702013.htm
    [9]
    袁春平, 侯惠民, 钱明英, 等. 渗透泵片剂的新型热塑包衣技术制备工艺的开发[J]. 中国医药工业杂志, 2019, 50(1): 48-58. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHOU201901005.htm
    [10]
    安欣欣, 周洪雷, 李传厚, 等. 口服渗透泵控释制剂的研究进展[J]. 中国药房, 2018, 29(22): 3165-3168. doi: 10.6039/j.issn.1001-0408.2018.22.30
    [11]
    褚晓杰. 肠溶型阿司匹林与普通阿司匹林胃肠道不良反应分析[J]. 中国现代药物应用, 2018, 12(13): 162-163. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY201813092.htm
    [12]
    刘毓婷, 苏峰, 刘为中, 等. 缓控释微丸制剂的研究进展[J]. 广州化工, 2017, 45(24): 34-36. doi: 10.3969/j.issn.1001-9677.2017.24.013
    [13]
    吉顺莉, 徐安保, 吴伟. 右旋雷贝拉唑钠肠溶微丸的制备及体外释放度考察[J]. 中国药师, 2016, 19(4): 797-800. doi: 10.3969/j.issn.1008-049X.2016.04.057
    [14]
    CHEN T, LI J, CHEN T, et al. Tablets of multi-unit pellet system for controlled drug delivery[J]. J Control Release, 2017, 262: 222-231. doi: 10.1016/j.jconrel.2017.07.043
    [15]
    AVILA-SALAS F, RODRIGUEZ NUÑEZ Y A, Marican A, et al. Rational development of a novel hydrogel as a ph-sensitive controlled release system for nifedipine[J]. Polymers (Basel), 2018, 10(7): 806. doi: 10.3390/polym10070806
    [16]
    El-MASRY S M, El-KHODARY N M. Pharmacokinetic and tolerability comparison of sustained and immediate release oral formulations of nifedipine tablet formulations: A single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting egyptian male volunteers[J]. Drug Res (Stuttg), 2020, 70(2-03): 91-96.2020.
    [17]
    2019 American Geriatrics Society Beers Criteria? Update Expert Panel. American geriatrics society 2019 updated ags beers criteria for potentially inappropriate medication use in older adults[J]. J Am Geriatr Soc, 2019, 67(4): 674-694. doi: 10.1111/jgs.15767
    [18]
    ACOG. Committee opinion no. 767: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period[J]. Obstet Gynecol, 2019, 133(2): e174-e180.
    [19]
    蔡畅. 硝苯地平缓释片与硝苯地平控释片治疗原发性高血压患者的疗效对比[J]. 中国现代药物应用, 2019, 13(22): 149-151. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY201922088.htm
    [20]
    李茜娴. 硝苯地平缓释片与控释片治疗妊娠期高血压疗效对比探讨[J]. 现代诊断与治疗, 2019, 30(10): 1625-1627. https://www.cnki.com.cn/Article/CJFDTOTAL-XDZD201910020.htm
    [21]
    刘静哲. 硝苯地平缓释片与硝苯地平控释片治疗原发性高血压的效果研究[J]. 中国医药指南, 2018, 16(27): 160-161. https://www.cnki.com.cn/Article/CJFDTOTAL-YYXK201827128.htm
    [22]
    潘远安, 刘江红, 张志超, 等. 硝苯地平缓释片与硝苯地平控释片治疗高血压合并糖尿病的疗效比较[J]. 现代诊断与治疗, 2017, 28(7): 1225-1227. doi: 10.3969/j.issn.1001-8174.2017.07.032
    [23]
    孙海凤. 高血压患者选取硝苯地平缓释片与硝苯地平控释片治疗的疗效对比[J]. 临床医药文献电子杂志, 2018, 5(82): 75, 78. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWX201882053.htm
    [24]
    田凤莲, 肖忠琴. 硝苯地平缓释片与硝苯地平控释片治疗高血压的效果对比[J]. 医药前沿, 2019, 9(31): 58-59. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY201922088.htm
    [25]
    杨伟. 硝苯地平控释片对原发性高血压的血压控制效果[J]. 中国保健营养, 2019, 29(28): 112-113. https://www.cnki.com.cn/Article/CJFDTOTAL-YXLL202019021.htm
    [26]
    GAO Z, NGO C, YE W, et al. Effects of dissolution medium ph and simulated gastrointestinal contraction on drug release from nifedipine extended-release tablets[J]. J Pharm Sci, 2019, 108(3): 1189-1194. doi: 10.1016/j.xphs.2018.10.014
    [27]
    张继睿, 董阳雨, 韩清, 等. 聚维酮和共聚维酮为载体的硝苯地平渗透泵片的制备[J]. 药学研究, 2018, 37(7): 397-400. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYG201807008.htm
    [28]
    陈飞, 王超, 高昊. 推拉式渗透泵药物传递系统处方设计关键要素研究[J]. 中国药学杂志, 2019, 54(10): 783-789. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYX201910006.htm
    [29]
    黄晓. 硝苯地平缓释片、控释片如何选择[N]. 家庭医生报, 2016-05-09(006).
    [30]
    朱映华. 琥珀酸美托洛尔缓释片与酒石酸美托洛尔片治疗慢性心力衰竭临床疗效的meta分析[J]. 中国实用医药, 2018, 13(10): 108-109. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201810061.htm
    [31]
    凡春红. 琥珀酸美托洛尔缓释片与酒石酸美托洛尔片治疗老年不稳定型心绞痛的效果观察[J]. 海峡药学, 2019, 31(5): 155-156. doi: 10.3969/j.issn.1006-3765.2019.05.076
    [32]
    VINEREANU D, SPINAR J, PATHAK A, et al. Role of metoprolol succinate in the treatment of heart failure and atrial fibrillation: A systematic review[J]. Am J Ther, 2019. DOI: 10.1097/MJT.0000000000001043
    [33]
    于丽丽, 杨懿群, 刘禹宏, 等. 基于渗透压释药原理的混合骨架控释片研究[J]. 中国药业, 2017, 26(19): 9-13. doi: 10.3969/j.issn.1006-4931.2017.19.003
    [34]
    上海卡乐康包衣技术有限公司. 乙基纤维素干粉包衣的美托洛尔缓释多颗粒的稳定性评估[J]. 中国医药工业杂志, 2018, 49(8): 后插1-后插3.
    [35]
    于红霞, 周珏, 唐珍凤. 酒石酸美托洛尔缓释片的制备[J]. 天津化工, 2016, 30(2): 39, 45. https://www.cnki.com.cn/Article/CJFDTOTAL-TJHG201602014.htm
    [36]
    MALIPEDDI V R, AWASTHI R, DUA K. Formulation and evaluation of controlled release ethylcellulose and polyethylene glycol microspheres containing metoprolol tartrate[J]. Interv Med Appl Sci, 2016, 8(2): 60-67. doi: 10.1556/1646.8.2016.2.6
    [37]
    刘泽华, 肖宛璐, 邸东华, 等. 易溶性药物酒石酸美托洛尔速释联合缓释片的制备[J]. 沈阳药科大学学报, 2016, 33(8): 604-608. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYD201608003.htm
    [38]
    龚健, 徐彦, 赖鹏, 等. 高端口服固体仿制药的设计及其产品关键质量属性的控制——以FDA批准的琥珀酸美托洛尔缓释片为例[J]. 药学进展, 2018, 42(9): 644-654. https://www.cnki.com.cn/Article/CJFDTOTAL-YXJZ201809002.htm
    [39]
    HIEW T N, TIAN Y H, TAN H M, et al. A mechanistic understanding of compression damage to the dissolubility of coated pellets in tablets[J]. Eur J Pharm Biopharm, 2020, 146: 93-100. doi: 10.1016/j.ejpb.2019.11.006
    [40]
    MOHYLYUK V, PATEL K, SCOTT N, et al. Wurster fluidised bed coating of microparticles: Towards scalable production of oral sustained-release liquid medicines for patients with swallowing difficulties[J]. AAPS Pharm Sci Tech, 2019, 21(1): 3. doi: 10.1208/s12249-019-1534-5?utm_source=trendmd
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (266) PDF downloads(12) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return